论文部分内容阅读
目的探讨胰激肽原酶联合甲钴胺治疗糖尿病神经原性膀胱的效果。方法治疗组甲钴胺500ug 1次/d,im联合胰激肽原酶肠溶片120u,tid,po;对照组日1次im,维生素B_(12)针500ug,两组其他基础治疗相同,治疗前及治疗后的1个月、2个月检测残余尿量、最大尿流率、平均尿流率及排尿期逼尿肌压。结果治疗组治疗后1个月残余尿量显著降低,最大尿流率、平均尿流率及排尿期逼尿肌压均显著增加(P<0.05);对照组各项结果较治疗前无统计学差异(P>0.05),治疗后2个月残余尿量轻度降低,最大尿流率及排尿期逼尿肌压升高,较治疗前差异有统计学意义(P<0.05),治疗组与对照组比较,残余尿量更低,最大尿流率、平均尿流率及排尿期逼尿肌压更高,差异有统计学意义(P<0.05)。结论胰激肽原酶联合甲钴胺治疗糖尿病神经原性膀胱疗效显著。
Objective To investigate the effect of pancreatic kallikrein combined with mecobalamin in the treatment of diabetic neurogenic bladder. Methods The treatment group mecobalamin 500ug 1 / d, im combined pancreatic kininogenase enteric-coated tablets 120u, tid, po; control group on the 1st im, vitamin B 12 needle 500ug, the other two groups of the same basic treatment, Before treatment and after treatment for 1 month, 2 months to detect residual urine volume, the maximum flow rate, the average flow rate of urine and urinary detrusor pressure. Results The residual urine volume of the treatment group decreased significantly at 1 month after treatment, and the maximum urinary flow rate, mean urinary flow rate and urinary urinary burst pressure were significantly increased (P <0.05). The results of the control group were no statistical difference (P> 0.05). After 2 months of treatment, the residual urine volume decreased slightly, the maximal uroflow rate and urinary urinary bursa pressure increased (P <0.05), the difference between the two groups was statistically significant Compared with the control group, the residual urine volume was lower, the maximum urinary flow rate, mean urinary flow rate and urinary urinary burst pressure were higher, the difference was statistically significant (P <0.05). Conclusions Pancreatic kallikrein combined with mecobalamin has significant therapeutic effect on diabetic neurogenic bladder.